Clinical trial · Interventional
Amlodipine on Blood Flow of Preovulatory Follicle in Polycystic Ovarian Patients
Effect of Amlodipine and Clomid on Blood Flow of Preovulatory Follicle in Polycystic Ovarian Patients
NCT02544776CI-TRIAL-00021501completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
On the basis of the current study, amlodipine seems to be a promising drug on improving uterine, ovarian blood flow, size of pre-ovulatory follicle, midluteal progesterone level and pregnancy outcome in patients with pco.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Female Infertility Associated With Anovulation | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Amlodipine | Drug | — | UNRESOLVED |
| Clomifene citrate ( clomid 50 mg ) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Clomifene citrate and Amlodipine
- description
- Amlodipine 5mg tablet and Clomifene citrate 50 mg tablet once by mouth daily at morning starting from day number 5 of menstrual cycle till day number 9.
- interventionNames
- Drug: Clomifene citrate ( clomid 50 mg )
- Drug: Amlodipine
- type
- ACTIVE_COMPARATOR
- label
- Clomifene citrate
- description
- Clomifene citrate 50mg and once daily at morning starting from day number 5 of menstrual cycle till day number 9
- interventionNames
- Drug: Clomifene citrate ( clomid 50 mg )
Primary outcomes (1)
- measure
- change in ovarian artery perfusion
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 35 Years
Show eligibility criteria text
Inclusion Criteria: * Demographic features including females in age of ≥20 \& ≤35, and BMI of ≤39. * Infertility secondary to polycystic ovary , The choice of polycystic ovary patients will be according to the Rotterdam consensus workshop (Rotterdam, 2004), and the diagnosis of polycystic ovary by ultrasonography will be made according to Adams et al. criteria which are the most often cited (Adams et al., 1985).The Rotterdam criteria as follows: * Oligo- or anovulation. * Clinical and/or biochemical signs of hyper androgynism * The presence of polycystic ovaries on ultrasound scan. Ultrasound findings of enlarged ovaries with multiple small cysts (10-12 or more of 2-9 mm in diameter) scattered around the periphery and highly echogenic stroma Exclusion Criteria: * Including other causes of infertility diagnosed during infertility work up. * Patients refused to participate or to continue study. * Also, hepatic, cardiac, and hypotensive patients will be excluded from the study.
References
Publications (0)
Data not yet available
No reference posted for this study.